Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2013

Open Access 01-12-2013 | Research

Bone-stromal cells up-regulate tumourigenic markers in a tumour-stromal 3D model of prostate cancer

Authors: Louisa CE Windus, Tristan T Glover, Vicky M Avery

Published in: Molecular Cancer | Issue 1/2013

Login to get access

Abstract

Background

The cellular and molecular mechanisms that mediate interactions between tumour cells and the surrounding bone stroma are to date largely undetermined in prostate cancer (PCa) progression. The purpose of this study was to evaluate the role of alpha 6 and beta 1 integrin subunits in mediating tumour-stromal interactions.

Methods

Utilising 3D in vitro assays we evaluated and compared 1. Monocultures of prostate metastatic PC3, bone stromal derived HS5 and prostate epithelial RWPE-1 cells and 2. Tumour-stromal co-cultures (PC3 + HS5) to ascertain changes in cellular phenotype, function and expression of metastatic markers.

Results

In comparison to 3D monocultures of PC3 or HS5 cells, when cultured together, these cells displayed up-regulated invasive and proliferative qualities, along with altered expression of epithelial-to-mesenchymal and chemokine protein constituents implicated in metastatic dissemination. When co-cultured, HS5 cells were found to re-express N-Cadherin and chemokine receptor CXCR7. Alterations in N-Cadherin expression were found to be mediated by soluble factors secreted by PC3 tumour cells, while chemokine receptor re-expression was dependent on direct cell-cell interactions. We have also shown that integrins beta 1 and alpha 6 play an integral role in maintaining cell homeostasis and mediating expression of E-Cadherin, N-Cadherin and vimentin, in addition to chemokine receptor CXCR7.

Conclusions

Collectively our results suggest that both PC3 and HS5 cells provide a “protective” and reciprocal milieu that promotes tumour growth. As such 3D co-cultures may serve as a more complex and valid biological model in the drug discovery pipeline.
Appendix
Available only for authorised users
Literature
1.
Mendoza M, Khanna C: Revisiting the seed and soil in cancer metastasis. Int J Biochem Cell Biol. 2009, 41: 1452-1462.CrossRefPubMed
2.
Langley RR, Fidler IJ: The seed and soil hypothesis revisited–the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer. 2011, 128: 2527-2535.PubMedCentralCrossRefPubMed
3.
Harma V, Virtanen J, Makela R, Happonen A, Mpindi JP, Knuuttila M, Kohonen P, Lotjonen J, Kallioniemi O, Nees M: A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responses. PLoS One. 2010, 5: e10431-PubMedCentralCrossRefPubMed
4.
Windus LC, Kiss DL, Glover T, Avery VM: In vivo biomarker expression patterns are preserved in 3D cultures of Prostate Cancer. Exp Cell Res. 2012, 318: 2507-2519.CrossRefPubMed
5.
Sung SY, Hsieh CL, Law A, Zhau HE, Pathak S, Multani AS, Lim S, Coleman IM, Wu LC, Figg WD: Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. Cancer Res. 2008, 68: 9996-10003.PubMedCentralCrossRefPubMed
6.
Rhee HW, Zhau HE, Pathak S, Multani AS, Pennanen S, Visakorpi T, Chung LW: Permanent phenotypic and genotypic changes of prostate cancer cells cultured in a three-dimensional rotating-wall vessel. In Vitro Cell Dev Biol Anim. 2001, 37: 127-140.CrossRefPubMed
7.
Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN: Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001, 410: 50-56.CrossRefPubMed
8.
Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK: Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 2002, 62: 1832-1837.PubMed
9.
Wang J, Shiozawa Y, Wang Y, Jung Y, Pienta KJ, Mehra R, Loberg R, Taichman RS: The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem. 2008, 283: 4283-4294.CrossRefPubMed
10.
11.
Hall CL, Dubyk CW, Riesenberger TA, Shein D, Keller ET, van Golen KL: Type I collagen receptor (alpha2beta1) signaling promotes prostate cancer invasion through RhoC GTPase. Neoplasia. 2008, 10: 797-803.PubMedCentralCrossRefPubMed
12.
Lang SH, Clarke NW, George NJ, Testa NG: Primary prostatic epithelial cell binding to human bone marrow stroma and the role of alpha2beta1 integrin. Clin Exp Metastasis. 1997, 15: 218-227.CrossRefPubMed
13.
Van der Velde-Zimmermann D, Verdaasdonk MA, Rademakers LH, De Weger RA, Van den Tweel JG, Joling P: Fibronectin distribution in human bone marrow stroma: matrix assembly and tumor cell adhesion via alpha5 beta1 integrin. Exp Cell Res. 1997, 230: 111-120.CrossRefPubMed
14.
King TE, Pawar SC, Majuta L, Sroka IC, Wynn D, Demetriou MC, Nagle RB, Porreca F, Cress AE: The role of alpha 6 integrin in prostate cancer migration and bone pain in a novel xenograft model. PLoS One. 2008, 3: e3535-PubMedCentralCrossRefPubMed
15.
Schmelz M, Cress AE, Scott KM, Burger F, Cui H, Sallam K, McDaniel KM, Dalkin BL, Nagle RB: Different phenotypes in human prostate cancer: alpha6 or alpha3 integrin in cell-extracellular adhesion sites. Neoplasia. 2002, 4: 243-254.PubMedCentralCrossRefPubMed
16.
Ports MO, Nagle RB, Pond GD, Cress AE: Extracellular engagement of alpha6 integrin inhibited urokinase-type plasminogen activator-mediated cleavage and delayed human prostate bone metastasis. Cancer Res. 2009, 69: 5007-5014.PubMedCentralCrossRefPubMed
17.
Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA: A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res. 2007, 13: 7003-7011.CrossRefPubMed
18.
Thompson EW, Newgreen DF, Tarin D: Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition?. Cancer Res. 2005, 65: 5991-5995. discussion 5995CrossRefPubMed
19.
Trimboli AJ, Fukino K, de Bruin A, Wei G, Shen L, Tanner SM, Creasap N, Rosol TJ, Robinson ML, Eng C: Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res. 2008, 68: 937-945.CrossRefPubMed
20.
Giampieri S, Manning C, Hooper S, Jones L, Hill CS, Sahai E: Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol. 2009, 11: 1287-1296.PubMedCentralCrossRefPubMed
21.
Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH: EMT and dissemination precede pancreatic tumor formation. Cell. 2012, 148: 349-361.PubMedCentralCrossRefPubMed
22.
Chaffer CL, Brennan JP, Slavin JL, Blick T, Thompson EW, Williams ED: Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res. 2006, 66: 11271-11278.CrossRefPubMed
23.
Bonnomet A, Syne L, Brysse A, Feyereisen E, Thompson EW, Noel A, Foidart JM, Birembaut P, Polette M, Gilles C: A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer. Oncogene. 2012, 31: 3741-3753.CrossRefPubMed
24.
25.
Carlini MJ, De Lorenzo MS, Puricelli L: Cross-talk between tumor cells and the microenvironment at the metastatic niche. Curr Pharm Biotechnol. 2011, 12: 1900-1908.CrossRefPubMed
26.
He H, Yang X, Davidson AJ, Wu D, Marshall FF, Chung LW, Zhau HE, Wang R: Progressive epithelial to mesenchymal transitions in ARCaP E prostate cancer cells during xenograft tumor formation and metastasis. Prostate. 2010, 70: 518-528.PubMedCentralCrossRefPubMed
27.
Ono M, Kubota S, Fujisawa T, Sonoyama W, Kawaki H, Akiyama K, Oshima M, Nishida T, Yoshida Y, Suzuki K: Promotion of attachment of human bone marrow stromal cells by CCN2. Biochem Biophys Res Commun. 2007, 357: 20-25.CrossRefPubMed
28.
Kiss DL, Windus LC, Avery VM: Chemokine receptor expression on integrin-mediated stellate projections of prostate cancer cells in 3D culture. Cytokine. 2013, 64 (1): 122-130.CrossRefPubMed
29.
Hsieh CL, Gardner TA, Miao L, Balian G, Chung LW: Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells. Cancer Gene Ther. 2004, 11: 148-155.CrossRefPubMed
30.
Nabha SM, dos Santos EB, Yamamoto HA, Belizi A, Dong Z, Meng H, Saliganan A, Sabbota A, Bonfil RD, Cher ML: Bone marrow stromal cells enhance prostate cancer cell invasion through type I collagen in an MMP-12 dependent manner. Int J Cancer. 2008, 122: 2482-2490.CrossRefPubMed
31.
Zhang X, Fournier MV, Ware JL, Bissell MJ, Yacoub A, Zehner ZE: Inhibition of vimentin or beta1 integrin reverts morphology of prostate tumor cells grown in laminin-rich extracellular matrix gels and reduces tumor growth in vivo. Mol Cancer Ther. 2009, 8: 499-508.PubMedCentralCrossRefPubMed
32.
Wang R, Sun X, Wang CY, Hu P, Chu CY, Liu S, Zhau HE, Chung LW: Spontaneous cancer-stromal cell fusion as a mechanism of prostate cancer androgen-independent progression. PLoS One. 2012, 7: e42653-PubMedCentralCrossRefPubMed
33.
Lehr JE, Pienta KJ: Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. J Natl Cancer Inst. 1998, 90: 118-123.CrossRefPubMed
34.
Matesz C, Modis L, Halasi G, Szigeti ZM, Felszeghy S, Bacskai T, Szekely G: Extracellular matrix molecules and their possible roles in the regeneration of frog nervous system. Brain Res Bull. 2005, 66: 526-531.CrossRefPubMed
35.
Zhang C, Soori M, Miles FL, Sikes RA, Carson DD, Chung LW, Farach-Carson MC: Paracrine factors produced by bone marrow stromal cells induce apoptosis and neuroendocrine differentiation in prostate cancer cells. Prostate. 2011, 71: 157-167.PubMedCentralCrossRefPubMed
36.
37.
Garlick DS, Li J, Sansoucy B, Wang T, Griffith L, Fitzgerald T, Butterfield J, Charbonneau B, Violette SM, Weinreb PH: alpha (V) beta (6) integrin expression is induced in the POET and Pten (pc-/-) mouse models of prostatic inflammation and prostatic adenocarcinoma. Am J Transl Res. 2012, 4: 165-174.PubMedCentralPubMed
38.
Wang Z, Chui WK, Ho PC: Integrin targeted drug and gene delivery. Expert Opin Drug Deliv. 2010, 7: 159-171.CrossRefPubMed
39.
Sroka IC, Anderson TA, McDaniel KM, Nagle RB, Gretzer MB, Cress AE: The laminin binding integrin alpha6beta1 in prostate cancer perineural invasion. J Cell Physiol. 2010, 224: 283-288.CrossRefPubMed
40.
Guarino M, Rubino B, Ballabio G: The role of epithelial-mesenchymal transition in cancer pathology. Pathology. 2007, 39: 305-318.CrossRefPubMed
41.
Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002, 2: 442-454.CrossRefPubMed
42.
Cavallaro U: N-cadherin as an invasion promoter: a novel target for antitumor therapy?. Curr Opin Investig Drugs. 2004, 5: 1274-1278.PubMed
43.
Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y, Johnson KR: Cadherin switching. J Cell Sci. 2008, 121: 727-735.CrossRefPubMed
44.
Hulit J, Suyama K, Chung S, Keren R, Agiostratidou G, Shan W, Dong X, Williams TM, Lisanti MP, Knudsen K, Hazan RB: N-cadherin signaling potentiates mammary tumor metastasis via enhanced extracellular signal-regulated kinase activation. Cancer Res. 2007, 67: 3106-3116.CrossRefPubMed
45.
Nieman MT, Prudoff RS, Johnson KR, Wheelock MJ: N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J Cell Biol. 1999, 147: 631-644.PubMedCentralCrossRefPubMed
46.
Zavadil J, Bottinger EP: TGF-beta and epithelial-to-mesenchymal transitions. Oncogene. 2005, 24: 5764-5774.CrossRefPubMed
47.
Savagner P, Yamada KM, Thiery JP: The zinc-finger protein slug causes desmosome dissociation, an initial and necessary step for growth factor-induced epithelial-mesenchymal transition. J Cell Biol. 1997, 137: 1403-1419.PubMedCentralCrossRefPubMed
48.
Graham TR, Zhau HE, Odero-Marah VA, Osunkoya AO, Kimbro KS, Tighiouart M, Liu T, Simons JW, O'Regan RM: Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Can Res. 2008, 68: 2479-2488. 10.1158/0008-5472.CAN-07-2559.CrossRef
49.
Lee JG, Kay EP: FGF-2-mediated signal transduction during endothelial mesenchymal transformation in corneal endothelial cells. Exp Eye Res. 2006, 83: 1309-1316.CrossRefPubMed
50.
Leong KG, Niessen K, Kulic I, Raouf A, Eaves C, Pollet I, Karsan A: Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. J Exp Med. 2007, 204: 2935-2948.PubMedCentralCrossRefPubMed
51.
Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM: Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 2003, 3: 347-361.CrossRefPubMed
52.
Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W: Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature. 2003, 425: 307-311.CrossRefPubMed
53.
Daniels DL, Eklof Spink K, Weis WI: beta-catenin: molecular plasticity and drug design. Trends Biochem Sci. 2001, 26: 672-678.CrossRefPubMed
Metadata
Title
Bone-stromal cells up-regulate tumourigenic markers in a tumour-stromal 3D model of prostate cancer
Authors
Louisa CE Windus
Tristan T Glover
Vicky M Avery
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2013
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-12-112

Other articles of this Issue 1/2013

Molecular Cancer 1/2013 Go to the issue

Research

DKK1 promotes hepatocellular carcinoma cell migration and invasion through β-catenin/MMP7 signaling pathway

Review

The roles of FOXM1 in pancreatic stem cells and carcinogenesis

Research

1H-NMR based metabonomic profiling of human esophageal cancer tissue

Research

Cathepsin B as a potential prognostic and therapeutic marker for human lung squamous cell carcinoma

Review

Cancer risk in immune-mediated inflammatory diseases (IMID)

Short communication

Gene expression profiling of chronic myeloid leukemia with variant t(9;22) reveals a different signature from cases with classic translocation
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits